

Comprehensive Diabetes Care (CDC): Medical Attention for Nephropathy

Patient Profile

MVP members 18–75 years of age with Diabetes (Type 1 and Type 2) and who have had a nephropathy screening or monitoring test, OR evidence of nephropathy documented in the medical record annually.

This includes documentation of one of the following each year:

- A nephropathy screening or monitoring test (any urine test for albumin or protein).
- Evidence of treatment for nephropathy OR ACE/ARB therapy.
- Documentation of medical attention for diabetic nephropathy, renal insufficiency, proteinuria, albuminuria, renal dysfunction, CKD, or ARF.
- A visit with a Nephrologist.
- Evidence of Stage IV CKD, ESRD, dialysis, or a kidney transplant.

Refer to the *Comprehensive Diabetes Care (CDC) Overview* Tip Sheet for exclusions to this sub-measure.



How to Implement Best Practices and Improve Performance

- A current medication list in the chart indicating that a patient is on an ACE/ARB agent will satisfy the requirement for medical attention to nephropathy.
- A urine dipstick (for protein) provided annually in your office will also satisfy this requirement. Be sure to submit a claim for it.
- Coordinate an exchange of information with specialists such as Nephrologists and Endocrinologists. Engage providers out of the area that may care for patients at a seasonal location.
- Consult the *MVP Gaps in Care Report (GIC)* for a list of delinquent CDC-Nephropathy members.
- Enable electronic medical record alerts for staff to prevent delinquent testing, reports, and visits.
- Consider the use and maintenance of a Diabetes Flowchart for efficient Nephropathy tracking.
- Exchange laboratory data with your local Regional Health Information Organization (RHIO).

Information related to all 2019 HEDIS measures has been extracted from the NCQA 2019 HEDIS Technical Specifications Volume 2.

A claim for any of the following medications will satisfy the medical attention for nephropathy requirement. For information on medications covered by MVP, see the *MVP Medicaid Drug Formulary* available by visiting mvphealthcare.com and selecting *Providers*, then *Pharmacy*, then *MVP Formularies*.

ACE Inhibitor/ARB Medications

Visit ncqa.org for a comprehensive list of ACE Inhibitor/ARB Medications.

Angiotensin Converting Enzyme Inhibitors	Benazepril Moexipril	Captopril Perinfopril	Enalapril Quinapril	Fosinopril Ramipril	Lisinopril Trandolapril
Angiotensin II Inhibitors	Azilsartan Olmesartan	Candesartan Telmisartan	Eprosaran Valsartan	Irbesartan	Losartan
Antihypertensive Combinations	Aliskiren-valsartan Amlodipine-benazepril Amlodipine-hydrochlorothiazide-olmesartan Amlodipine-hydrochlorothiazide-valsartan Amlodipine-olmesartan Amlodipine-perindopril Amlodipine-telmisartan Amlodipine-valsartan Azilsartan-chlorthalidone Benazepril-hydrochlorothiazide Candesartan-hydrochlorothiazide Captopril-hydrochlorothiazide		Enalapril-hydrochlorothiazide Eprosartan-hydrochlorothiazide Fosinopril-hydrochlorothiazide Hydrochlorothiazide-irbesartan Hydrochlorothiazide-lisinopril Hydrochlorothiazide-losartan Hydrochlorothiazide-moexipril Hydrochlorothiazide-olmesartan Hydrochlorothiazide-quinapril Hydrochlorothiazide-telmisartan Hydrochlorothiazide-valsartan Sacubitril-valsartan Trandolapril-verapamil		

Use of drugs listed here will score the sub-measure as compliant. Remember to reference the MVP Formulary to learn which of these medications are covered by the member's plan.

Billing Codes

Medical Attention for Nephropathy

CPT Codes

Urine Macroalbumin Tests

8100–81003, 81005, 82042–82044, 84156

CPT Category II Codes

Positive Urine Macroalbumin Tests

3060F, 3062F

Negative Urine Macroalbumin Tests

3061F

Evidence of Treatment for Nephropathy

Nephropathy Screening Tests

81000–81003, 81005, 82042–82044, 84156

CPT Category II Codes

Nephropathy Screening Test

3060F, 3061F

Treatment for Nephropathy

3066F, 4010F